Search research articles
Contact Us
Filters
Showing results (761-770 of 803) with videos related to
Page
of 81
Sort By:
Pediatric Neurology
|
August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial
Laura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Human Mutation
|
April 14, 2025
Targeted Genomic Sequencing of <i>TSC1</i> and <i>TSC2</i> Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal
Hannah D West, Mark Nellist, Rutger W W Brouwer, et al.
Tobacco Control
|
June 1, 2023
Policy-relevant differences between secondhand and thirdhand smoke: strengthening protections from involuntary exposure to tobacco smoke pollutants
Georg E Matt, Lydia Greiner, Rachael A Record, et al.
Pediatric Neurology
|
March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT Study
Tarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Plos One
|
April 30, 2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
Cheryl A London, Heather L Gardner, Tamra Mathie, et al.
Journal of Medicinal Chemistry
|
April 30, 2026
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
Ryan V Quiroz, Simon B Lang, Rebecca E Johnson, et al.
Journal of Medicinal Chemistry
|
February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met
Alan B Northrup, Matthew H Katcher, Michael D Altman, et al.
The Journal of Biological Chemistry
|
December 2, 2010
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor
Kumiko Nagashima, Stuart D Shumway, Sriram Sathyanarayanan, et al.
Journal of Medicinal Chemistry
|
January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors
J Michael Ellis, Michael D Altman, Alan Bass, et al.
Cancer Research
|
April 16, 2011
PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models
Katharine Ellwood-Yen, Heike Keilhack, Kaiko Kunii, et al.
Page
of 81
Search research articles
Search
Showing results (761-770 of 803) with videos related to
Sort By:
Page
of 81
Pediatric Neurology
|
August 14, 2024
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial
Laura S Farach, Melissa A Richard, Aynara C Wulsin, et al.
Human Mutation
|
April 14, 2025
Targeted Genomic Sequencing of <i>TSC1</i> and <i>TSC2</i> Reveals Causal Variants in Individuals for Whom Previous Genetic Testing for Tuberous Sclerosis Complex Was Normal
Hannah D West, Mark Nellist, Rutger W W Brouwer, et al.
Tobacco Control
|
June 1, 2023
Policy-relevant differences between secondhand and thirdhand smoke: strengthening protections from involuntary exposure to tobacco smoke pollutants
Georg E Matt, Lydia Greiner, Rachael A Record, et al.
Pediatric Neurology
|
March 29, 2026
Early Vigabatrin Treatment Before Seizure Onset Decreased Interictal Epileptiform Discharges Over the Duration of the PREVeNT Study
Tarrant O McPherson, E Martina Bebin, Laura S Farach, et al.
Plos One
|
April 30, 2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
Cheryl A London, Heather L Gardner, Tamra Mathie, et al.
Journal of Medicinal Chemistry
|
April 30, 2026
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
Ryan V Quiroz, Simon B Lang, Rebecca E Johnson, et al.
Journal of Medicinal Chemistry
|
February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met
Alan B Northrup, Matthew H Katcher, Michael D Altman, et al.
The Journal of Biological Chemistry
|
December 2, 2010
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor
Kumiko Nagashima, Stuart D Shumway, Sriram Sathyanarayanan, et al.
Journal of Medicinal Chemistry
|
January 28, 2015
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors
J Michael Ellis, Michael D Altman, Alan Bass, et al.
Cancer Research
|
April 16, 2011
PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models
Katharine Ellwood-Yen, Heike Keilhack, Kaiko Kunii, et al.
Page
of 81